Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study
- 1 November 2004
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (16) , 2432-2438
- https://doi.org/10.1016/j.ejca.2004.08.004
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancerAnnals of Oncology, 2004
- Primary endpoint analysis of the GEPARDUO study: Comparing dose-dense with sequential adriamycin/docetaxel combination as preoperative chemotherapy (PCHT) in operable breast cancer (T2-3, N0-2, M0)The Breast, 2003
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With DocetaxelJournal of Clinical Oncology, 2002
- Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18JNCI Monographs, 2001
- Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*Breast Cancer Research and Treatment, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant ChemotherapyJournal of Clinical Oncology, 1999
- Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trialAnnals of Oncology, 1999
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998
- Gemcitabine—a safety reviewAnti-Cancer Drugs, 1998